Health and Fitness Health and Fitness
Tue, February 21, 2012
[ Tue, Feb 21st 2012 ] - Market Wire
Hospira Works With FDA to Help Avert Methotrexate .. One Month's Supply of New Product Immediately and
[ Tue, Feb 21st 2012 ] - Market Wire
Community Health Systems, Inc. to Participate in Two Investor Conferences in February
[ Tue, Feb 21st 2012 ] - Market Wire
American Oriental Bioengineering Inc. Announces Plans for Reverse Stock Split of its Common Stock
[ Tue, Feb 21st 2012 ] - Market Wire
Quest Diagnostics Offers Industry-First 30-Day Am .. R Implementation Guarantee for Hospitals and IDNs
[ Tue, Feb 21st 2012 ] - Market Wire
MIT Receives First ARRONAX Shipment, Launching Strontium-82 Validation Project
[ Tue, Feb 21st 2012 ] - Market Wire
BRILINTA (ticagrelor) Added to American College o .. tions on Antithrombotic Therapy and Prevention of
[ Tue, Feb 21st 2012 ] - Market Wire
IGSM Group INC. Lays the Foundation for the Master Plan of a Holding Company
[ Tue, Feb 21st 2012 ] - Market Wire
ImmunoCellular, Willis Group Holdings, Encana, Exxon Mobil and Cenovus Energy
[ Tue, Feb 21st 2012 ] - Market Wire
Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
[ Tue, Feb 21st 2012 ] - Market Wire
Gilead Sciences, Chesapeake Energy, Wells Fargo, Applied Materials, and Pfizer
[ Tue, Feb 21st 2012 ] - Market Wire
Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic Malignancies
[ Tue, Feb 21st 2012 ] - Market Wire
Peter A. Marmerstein Appointed President of West Florida Division
[ Tue, Feb 21st 2012 ] - Market Wire
Boston Scientific, Alcoa, Alcatel-Lucent, Atmel, and Delta Air Lines
[ Tue, Feb 21st 2012 ] - Market Wire
Enzo Biochem Receives Approval for Novel Blood Based Test for Colorectal Cancer Risk
[ Tue, Feb 21st 2012 ] - Market Wire
Dehaier Medical Retains The Equity Group to Provide Investor Relations Services
[ Tue, Feb 21st 2012 ] - Market Wire
Genomma Lab Internacional Announces Non-binding P .. tige Brands Holdings for $16.60 Per Share in Cash
[ Tue, Feb 21st 2012 ] - Market Wire
Paladin Announces Strategic Partnership with Lith .. erging of South African Pharmaceutical Businesses
[ Tue, Feb 21st 2012 ] - Market Wire
EnteroMedics to Participate in 4th Annual Lazard Capital Markets Medical Technology Conference
[ Tue, Feb 21st 2012 ] - Market Wire
Theratechnologies Announces a Supply, Distributio .. ng Agreement With Actelion Pharmaceuticals Canada
[ Tue, Feb 21st 2012 ] - Market Wire
AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences
[ Tue, Feb 21st 2012 ] - Market Wire
Cytokinetics Announces Initiation of Phase I Clin .. tions of Omecamtiv Mecarbil in Healthy Volunteers
[ Tue, Feb 21st 2012 ] - Market Wire
Horizon Pharma to Present at the Cowen and Company Health Care Conference
[ Tue, Feb 21st 2012 ] - Market Wire
Response Genetics Regains NASDAQ Compliance
[ Tue, Feb 21st 2012 ] - Market Wire
Repligen Announces FDA Grant of Priority Review for SecreFloa" NDA
[ Tue, Feb 21st 2012 ] - Market Wire
China Cord Blood Corporation to Report Third Quar .. irst Nine Months of Fiscal 2012 Financial Results
[ Tue, Feb 21st 2012 ] - Market Wire
Salix Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
[ Tue, Feb 21st 2012 ] - Market Wire
PDL BioPharma to Present at Upcoming Conferences
[ Tue, Feb 21st 2012 ] - Market Wire
Oral Treprostinil New Drug Application Accepted by FDA for Review
[ Tue, Feb 21st 2012 ] - Market Wire
Oncolytics Biotech Inc. Enters into Sponsorship A .. for Randomized Phase II Study in Prostate Cancer
[ Tue, Feb 21st 2012 ] - Market Wire
Isis Pharmaceuticals to Present at the 2012 Citi Global Health Care Conference

Isis Pharmaceuticals to Present at the 2012 Citi Global Health Care Conference


Published on 2012-02-21 04:15:51 - Market Wire
  Print publication without navigation


Isis Pharmaceuticals to Present at the 2012 Citi Global Health Care Conference -- CARLSBAD, Calif., Feb. 21, 2012 /PRNewswire/ --

Isis Pharmaceuticals to Present at the 2012 Citi Global Health Care Conference

[ ]

CARLSBAD, Calif., Feb. 21, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]), the leader in antisense therapeutics, today announced that management will present a company overview at Citi's 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 2:00 p.m. ET at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [ www.isispharm.com ].  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]

Contributing Sources